Loading
A phase 2 trial of LM103 TILs Injection in non-small-cell lung cancer, run by Suzhou BlueHorse Therapeutics Co., Ltd., now recruiting.
A Phase II Trial of LM103 for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07444437 by Suzhou BlueHorse Therapeutics Co., Ltd., with 45 participants planned, started 2026-02-26 and due to reach its primary completion in 2027-12-31. Interventions recorded: LM103 TILs Injection and PD-1 / PD-L1 monoclonal antibody.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PD-L1, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Resectable stage I to III non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares PD-L1, PD-1, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/